TKG Advisors LLC Purchases 623 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

TKG Advisors LLC lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 99.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,247 shares of the pharmaceutical company's stock after buying an additional 623 shares during the period. TKG Advisors LLC's holdings in Vertex Pharmaceuticals were worth $548,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of VRTX. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $25,000. Highline Wealth Partners LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $27,000. Dunhill Financial LLC boosted its stake in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Finally, Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at $33,000. Institutional investors own 90.96% of the company's stock.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares of the company's stock, valued at $30,805,286.70. This represents a 0.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. BMO Capital Markets decreased their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a report on Friday, December 20th. UBS Group increased their price target on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. StockNews.com cut shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Finally, William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $505.61.

Vertex Pharmaceuticals Trading Up 0.8 %

Vertex Pharmaceuticals stock traded up $3.91 during mid-day trading on Friday, hitting $484.24. 1,369,932 shares of the company's stock were exchanged, compared to its average volume of 1,522,551. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $124.35 billion, a P/E ratio of -220.11, a PEG ratio of 2.07 and a beta of 0.41. The company's 50 day simple moving average is $435.64 and its 200-day simple moving average is $460.65.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.58 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.